RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Progression-Free Survival Not Improved with Cabazitaxel versus Topotecan in Refractory SCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 13
OP 14
DO 10.1177/155989771403008
UL http://mdc.sagepub.com/content/14/3/13.abstract
AB A randomized, open-label Phase 2 trial with patients who had small cell lung cancer (SCLC) that had progressed during or after first-line platinum-based chemotherapy found no significant difference in progression-free survival with cabazitaxel against topotecan, the current standard for comparison [Riemsma R et al. BMC Cancer 2010]. The median overall survival was shorter for patients taking cabazitaxel versus those taking topotecan [NCT01500720].